DeepMed Research

STTG-003

Generic Name: STTG-003

Clinical Trials

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Phase 2

Recruiting

Conditions: Differentiated Thyroid Carcinoma

Interventions: Drug: ST-1898 tablets

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-11

Lead Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited

Target Recruit Count: 60

Registration Number: NCT06359847

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

A Study of ST-1898 for Unresectable or Metastatic Melanoma

Phase 1

Recruiting

Conditions: Unresectable or Metastatic Melanoma

Interventions: Drug: ST-1898 tablets

First Posted Date: 2024-04-11

Last Posted Date: 2024-04-11

Lead Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited

Target Recruit Count: 64

Registration Number: NCT06359860

Locations: 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, China

Study of ST-1898 in Advanced Renal Cell Carcinoma

Phase 1

Recruiting

Conditions: Advanced Renal Cell Carcinoma

Interventions: Drug: ST-1898 tablets

First Posted Date: 2023-11-13

Last Posted Date: 2023-11-13

Lead Sponsor: Beijing Scitech-Mq Pharmaceuticals Limited

Target Recruit Count: 90

Registration Number: NCT06127238

Locations: 🇨🇳
Peking University Cancer Hospital & Institute, Beijing, Beijing, China

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy